Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint

Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The ... Read More